These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28146132)

  • 41. Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
    Fukano Y; Kawazu K; Akaishi T; Bezwada P; Pellinen P
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):251-9. PubMed ID: 21491995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
    Hoy SM
    Drugs; 2015 Oct; 75(15):1807-13. PubMed ID: 26431840
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Receptors involved in the mechanism of action of topical prostaglandines].
    Neacsu AM
    Oftalmologia; 2009; 53(2):3-7. PubMed ID: 19697832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
    Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
    Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
    Sutton A; Gilvarry A; Ropo A
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):359-65. PubMed ID: 17803434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of prostaglandin analogues on intracellular Ca2+ in ciliary arteries of wild-type and prostanoid receptor-deficient mice.
    Abe S; Watabe H; Takaseki S; Aihara M; Yoshitomi T
    J Ocul Pharmacol Ther; 2013 Feb; 29(1):55-60. PubMed ID: 23046436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
    Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
    Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
    Kumagami T; Wakiyama H; Kusano M; Kajiyama A; Miura Y; Uematsu M; Yoneda A; Kurihara J; Suzuma K; Kitaoka T
    J Ocul Pharmacol Ther; 2014 May; 30(4):340-5. PubMed ID: 24576066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biomechanical Effects of Two Forms of PGF2α on Ex-vivo Rabbit Cornea.
    Zhu R; Zheng X; Guo L; Zhao Y; Wang Y; Wu J; Yu A; Wang J; Bao F; Elsheikh A
    Curr Eye Res; 2021 Apr; 46(4):452-460. PubMed ID: 32795212
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Equilibrium binding interactions between lotrafilcon a soft contact lenses and the two prostaglandin antiglaucoma drugs bimatoprost and tafluprost.
    Kenley RA; Filippone H; Giske M; Beidler D; Vehige J; Fleitman J
    Eye Contact Lens; 2013 Jul; 39(4):295-302. PubMed ID: 23771012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: synthesis and biological activity.
    Feng Z; Hellberg MR; Sharif NA; McLaughlin MA; Williams GW; Scott D; Wallace T
    Bioorg Med Chem; 2009 Jan; 17(2):576-84. PubMed ID: 19101156
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial.
    Chabi A; Baranak C; Lupinacci R; Herring WJ
    Int J Clin Pract; 2016 Jul; 70(7):577-86. PubMed ID: 27292765
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness.
    Hommer A; Schmidl D; Kromus M; Bata AM; Fondi K; Werkmeister RM; Baar C; Schmetterer L; Garhöfer G
    Eur J Ophthalmol; 2018 Jul; 28(4):385-392. PubMed ID: 29592773
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
    Li N; Chen XM; Zhou Y; Wei ML; Yao X
    Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost.
    Pellinen P; Lokkila J
    Ophthalmic Res; 2009; 41(2):118-22. PubMed ID: 19147999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface.
    Kanamoto T; Kiuchi Y; Tanito M; Mizoue S; Naito T; Teranishi S; Hirooka K; Rimayanti U;
    J Ocul Pharmacol Ther; 2015 Apr; 31(3):156-64. PubMed ID: 25710276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension].
    Karhanová M; Mlčák P; Fryšák Z; Marešová K
    Cesk Slov Oftalmol; 2012 Oct; 68(4):150-5. PubMed ID: 23214487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
    Crichton AC; Vold S; Williams JM; Hollander DA
    Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.
    Ota T; Aihara M; Saeki T; Narumiya S; Araie M
    Br J Ophthalmol; 2007 May; 91(5):673-6. PubMed ID: 17124244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.